BidaskClub lowered shares of Natus Medical (NASDAQ:BABY) from a buy rating to a hold rating in a report released on Wednesday.
BABY has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Natus Medical from a sell rating to a hold rating in a research note on Tuesday, December 25th. Roth Capital set a $36.00 target price on shares of Natus Medical and gave the stock a buy rating in a research note on Thursday, October 25th. William Blair restated a market perform rating on shares of Natus Medical in a research note on Saturday, January 12th. Finally, ValuEngine upgraded shares of Natus Medical from a hold rating to a buy rating in a research note on Thursday, January 10th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $36.00.
Shares of BABY stock opened at $34.09 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.89 and a current ratio of 2.62. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of 23.51 and a beta of 0.53. Natus Medical has a one year low of $27.69 and a one year high of $37.95.
In other news, Director Robert A. Gunst sold 14,750 shares of the stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $33.54, for a total transaction of $494,715.00. Following the transaction, the director now directly owns 32,392 shares in the company, valued at $1,086,427.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ken Ludlum sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $31.02, for a total transaction of $930,600.00. Following the transaction, the director now owns 73,957 shares in the company, valued at $2,294,146.14. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Factorial Partners LLC bought a new position in shares of Natus Medical during the third quarter valued at approximately $111,000. Sei Investments Co. boosted its stake in shares of Natus Medical by 46.3% during the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after purchasing an additional 1,478 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Natus Medical by 1,010.8% during the second quarter. Tower Research Capital LLC TRC now owns 5,132 shares of the medical equipment provider’s stock valued at $177,000 after acquiring an additional 4,670 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Natus Medical during the third quarter valued at approximately $204,000. Finally, Paloma Partners Management Co purchased a new stake in Natus Medical during the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 94.24% of the company’s stock.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
See Also: Bid-Ask Spread
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.